| Identification | Back Directory | [Name]
6-Fluoro-2-(2-methylphenyl)-1,2-benzisothiazol-3(2H)-one | [CAS]
727664-79-1 | [Synonyms]
6-Fluoro-2-(2-methylphenyl)-1,2-benzisothiazol-3(2H)-one | [Molecular Formula]
C14H10FNOS | [MOL File]
727664-79-1.mol | [Molecular Weight]
259.3 |
| Chemical Properties | Back Directory | [Boiling point ]
397.9±52.0 °C(Predicted) | [density ]
1.363±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 50mg/mL | [form ]
Solid | [pka]
-2.59±0.20(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Description]
Thr101, also known as NOX Inhibitor VII, is a dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9. Thr101 is also a NOX inhibitor. | [Uses]
Thr101 is an inhibitor (IC50=2.9 μM) of phosphomannose isomerase (PMI).PMI can compete with phosphomannose mutase 2 (PMM2) for the binding site of Man-6-P and convert mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) .Thr101 only specifically inhibits PMI and not PMM2. Thr101 can be used for research of congenital disorder of glycosylation type Ia (CDG-Ia)[1]. | [Definition]
ChEBI: 6-fluoro-2-(2-methylphenyl)-1,2-benzothiazol-3-one is a member of benzothiazoles. | [References]
[1] Dahl R, et al. Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem. 2011 May 26;54(10):3661-8. DOI:10.1021/jm101401a |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|